DOM-GABAPENTIN CAPSULE

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

GABAPENTIN

Доступна с:

DOMINION PHARMACAL

код АТС:

N02BF01

ИНН (Международная Имя):

GABAPENTIN

дозировка:

100MG

Фармацевтическая форма:

CAPSULE

состав:

GABAPENTIN 100MG

Администрация маршрут:

ORAL

Штук в упаковке:

100/500

Тип рецепта:

Prescription

Терапевтические области:

MISCELLANEOUS ANTICONVULSANTS

Обзор продуктов:

Active ingredient group (AIG) number: 0125929001; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2001-04-04

Характеристики продукта

PRODUCT MONOGRAPH
Pr DOM-GABAPENTIN
Gabapentin Capsules, House Standard
100 mg, 300 mg and 400 mg
Gabapentin Tablets, USP
600 mg and 800 mg
Antiepileptic Agent
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
Date of Revision:
August 11, 2017
Submission Control No.: 207318
_ _
_Dom-GABAPENTIN Product Monograph _
_Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................16
STORAGE AND STABILITY
..........................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
...............................................................................21
PHARMACEUTICAL INFORMATION
..........................................................................21
CLINICAL TRIALS
..........................................................................................................22
DETAILED PHARMACOLOG